Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr-Reference-Cited by-同舟云学术

Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fr

Published:2014-12-19 Issue:8 Volume:121 Page:1328-1338
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Lee Anne W.M.¹,Ngan Roger K.C.²,Tung Stewart Y.³,Cheng Ashley⁴,Kwong Dora L.W.⁵,Lu Tai-Xiang⁶,Chan Anthony T.C.⁷,Chan Lucy L.K.¹,Yiu Harry²,Ng Wai-Tong¹,Wong Frank³,Yuen Kam-Tong⁴,Yau Stephen²,Cheung Foon-Yiu²,Chan Oscar S.H.¹,Choi Horace⁸,Chappell Rick⁹

Affiliation:

1. Department of Clinical Oncology; Pamela Youde Nethersole Eastern Hospital; Hong Kong China

2. Department of Clinical Oncology; Queen Elizabeth Hospital; Hong Kong China

3. Department of Clinical Oncology; Tuen Mun Hospital; Hong Kong China

4. Department of Clinical Oncology; Princess Margaret Hospital; Hong Kong China

5. Department of Clinical Oncology, Queen Mary Hospital; University of Hong Kong; Hong Kong China

6. Department of Clinical Oncology; Sun Yat Sen University Cancer Center; Guangzhou, Guangdong China, China

7. Department of Clinical Oncology; Prince of Wales Hospital, Chinese University of Hong Kong; Hong Kong China

8. Department of Clinical Oncology; School of Public Health; University of Hong Kong; Hong Kong China

9. Department of Biostatistics; University of Wisconsin Medical School; Madison Wisconsin

Funder

Hong Kong Cancer Fund

Hong Kong Hospital Authority

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference28 articles.

1. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup Study 0099;Al-Sarraf;J Clin Oncol,1998

2. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#head-and-neck

3. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer stage III and IV nasopharyngeal cancer of the endemic variety;Wee;J Clin Oncol,2005

4. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma;Lee;J Natl Cancer Inst,2010

5. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China;Chen;Cancer,2013

Cited by 158 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Induction versus Adjuvant Chemotherapy Combined with Concurrent Chemoradiation: What Is Beneficial in Locally Advanced Nasopharyngeal Carcinoma—A 5-Year Comparative Study at a Tertiary Care Center in North India;South Asian Journal of Cancer;2024-06-10

2. Enhancing efficacy and reducing toxicity: Therapeutic optimization in locoregionally advanced nasopharyngeal carcinoma;Cell Reports Medicine;2024-06

3. Phase I dose-escalation study of nab-paclitaxel combined with cisplatin and capecitabin as induction chemotherapy followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma;Radiotherapy and Oncology;2024-02

4. Toripalimab plus capecitabine in the treatment of patients with residual nasopharyngeal carcinoma: a single-arm phase 2 trial;Nature Communications;2024-01-31

5. Indian clinical practice consensus guidelines for the management of nasopharyngeal cancer: Update 2022;Cancer Research, Statistics, and Treatment;2024-01